Which Factors Matter the Most? Revisiting and Dissecting Antibody Therapeutic Doses
Overview
Authors
Affiliations
Factors such as antibody clearance and target affinity can influence antibodies' effective doses for specific indications. However, these factors vary considerably across antibody classes, precluding direct and quantitative comparisons. Here, we apply a dimensionless metric, the therapeutic exposure affinity ratio (TEAR), which normalizes the therapeutic doses by antibody bioavailability, systemic clearance and target-binding property to enable direct and quantitative comparisons of therapeutic doses. Using TEAR, we revisited and dissected the doses of up to 60 approved antibodies. We failed to detect a significant influence of target baselines, turnovers or anatomical locations on antibody therapeutic doses, challenging the traditional perceptions. We highlight the importance of antibodies' modes of action for therapeutic doses and dose selections; antibodies that work through neutralizing soluble targets show higher TEARs than those working through other mechanisms. Overall, our analysis provides insights into the factors that influence antibody doses, and the factors that are crucial for antibodies' pharmacological effects.
Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies.
Robarge J, Budge K, Her L, Patterson A, Brown-Augsburger P Antibodies (Basel). 2025; 14(1.
PMID: 39846610 PMC: 11755617. DOI: 10.3390/antib14010002.
Green P, Schneider A, Lange J MAbs. 2024; 16(1):2402713.
PMID: 39279181 PMC: 11407384. DOI: 10.1080/19420862.2024.2402713.
Kulesza A, Couty C, Lemarre P, Thalhauser C, Cao Y J Pharmacokinet Pharmacodyn. 2024; 51(6):581-604.
PMID: 38904912 PMC: 11795844. DOI: 10.1007/s10928-024-09930-x.
De Sutter P, Gasthuys E, Vermeulen A J Pharmacokinet Pharmacodyn. 2023; 51(6):639-651.
PMID: 37952005 DOI: 10.1007/s10928-023-09894-4.
Chen C, Fan X, Zhang L, Xu P, Zou H, Zhao X Clin Pharmacokinet. 2023; 62(5):705-713.
PMID: 36930421 DOI: 10.1007/s40262-023-01231-9.